Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 5, 1999, Pages 491-499

  De Jonge, Maja J A ^a,b   Verweij, Jaap ^a,b   Loos, Walter J ^a,b   Dallaire, Brian K ^a,b   Sparreboom, Alex ^a,b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION FUNCTION; DRUG BIOAVAILABILITY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SALIVA;

EID: 0032962484     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70068-8     Document Type: Article

References (32)

1. 1. Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, Lim GA, et al. Plant antitumor agents; I: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-90.
2. 2. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
3. 3. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988;34:755-60.
4. 4. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 1970;54:461-70.
5. 5. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selanrig OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-21.
6. 6. Moertel CCG, Schutt AJ, Reitemeier RJ, Hatin RG. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:95-101.
7. 7. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992;8:676-84.
8. 8. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629-38.
9. 9. Takimoto CH, Klecker RW, Dahut W, Yee LK, Strong JM, Allegra CJ, et al. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr 1994;655:97-104.
10. 10. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994;37:40-6.
11. 11. Pantazis P, Kozielski AJ, Vardeman DM, Petry ER, Giovanella BC. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 1993;5:273-81.
12. 12. Giovanella BC, Stehlin JS, Hinz HR, Vardeman D, Mendoza JT, Potmesil M. Studies on time/dose intensity in treatment of human cancer xenografts with camptothecin analogues [abstract]. Proc Am Assoc Cancer Res 1994;35:455.
13. 13. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ, Stehlin JS, et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 1992;52:3980-7.
14. 14. De Souza PL, Cooper MR, Imondi AR, Myers CE. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin Cancer Res 1997;3:287-94.
15. 15. Supko JG, Malspeis L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res 1993;53:3062-9.
16. 16. Supko JG, Plowman J, Dykes DJ, Zaharko DS. Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC603071) antitumor activity in mice and its plasma pharmacokinetics [abstract]. Proc Am Assoc Cancer Res 1992;33:432.
17. 17. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995;1:269-76.
18. 18. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, et al. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 1996;14:1236-44.
19. 19. Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, et al. Pharmacokinetics and pharmacodynamics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 1997;15:1492-501.
20. 20. Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, et al. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times 4 every 5 weeks. J Clin Oncol 1998;16:1122-30.
21. 21. Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, et al. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res 1998;4:317-24.
22. 22. Hochster H, Liebes L, Speyer J, Sorich J, Chachoua A, Raphael B, et al. Phase I and pharmacodynamic study of prolonged infusion 9-amino-camptothecin (9AC) in two formulations [abstract] Proc Am Soc Clin Oncol 1997;16:201a.
23. 23. Sparreboom A, De Jonge MJA, Punt CJA, Nooter K, Loos WJ, Porro MG, et al. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. Clin Cancer Res 1998;4:1915-9.
24. 24. Loos WJ, Sparreboom A, Verweij J, Nooter K, Stoter G, Schellens JHM. Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1997;694:435-41.
25. 25. Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, et al. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol 1998;42:84-7.
26. 26. Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, De Boer-Dennert M, Davies B, et al. Bioavailability and pharmacokinetic of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996;73:1268-71.
27. 27. Gerrits CJH, Schellens JHM, Creemers GJ, Wissel PS, Planting AST, Pritchard JF, et al. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Br J Cancer 1997;76:946-51.
28. 28. Stewart CF, Zamboni WC, Crom WR, Houghton PJ. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 1997;40:259-65.
29. 29. Rivory LP, Chatelut E, Canal P, Mathieu-Boué A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11 ) and of its metabolite SN-38 in patients. Cancer Res 1994;54:6330-3.
30. 30. Punt CJA, de Jonge MJA, Sparreboom A, Loos WJ, van Beurden V, Planting AST, et al. Phase I and pharmacologic study on the topoisomerase I inhibitor [PEG-1000] 9-aminocamptothecin (9-AC) given orally to patients with solid rumors [abstract]. Proc Am Soc Clin Oncol 1998;17:197a.
31. 31. Takahashi T, Fujiwara Y, Sumiyoshi H, Isobe T, Yamaoka N, Yamakido M. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Cancer Chemother Pharmacol 1997;40:449-52.
32. 32. Sparreboom A, de Jonge MJA, Nooter K, Loos WJ, Porro MG, Stoter G, et al. Prediction of the systemic exposure to oral 9-aminocamptothecin PEG 1000 using limited-sampling models [abstract]. Proc Am Assoc Cancer Res 1998;39:363-4.